
10 New Clinical Trials Available at Texas Retina
In the last two decades, medical researchers have made significant advances in the diagnosis and treatment of retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision.
read more
March is Workplace Eye Wellness Month
In honor of March’s designation as Workplace Eye Wellness Month by the American Academy of Ophthalmology, here are a few tips on how to avoid digital eye strain: Make taking breaks a
read more
Dr. Wang Presents to State of Texas Association of Rheumatologists
This past weekend, Texas Retina’s Robert C. Wang presented “Uveitis: Everything Everywhere All at Once” at the State of Texas Association of Rheumatologists (STAR) 2025 Annual Meeting held at the Gaylord Texan
read more
We Love Our Patients!
At Texas Retina, our patients are at the HEART of everything we do. Thank you for placing your trust in us. Happy Valentine’s Day!
read more
Honoring the Life and Legacy of Texas Retina Co-founder Albert Vaiser, MD
It is with great sadness that Texas Retina announces the passing of one of its three founders, Albert Vaiser MD, on Saturday, February 1, 2025, after a brief illness. Dr. Vaiser had celebrated
read more
Understanding Your Insurance Coverage in the New Year: How Prior Authorizations Can Impact Retina Care
Health insurance policies and coverage vary greatly. As we start a new year, it is important to understand how your specific plan works and how that can affect your retina care. Referrals
read more
Office Closures for 1/10/2025
Due to the winter weather, the following Texas Retina offices are CLOSED today, January 10, 2025: Dallas North Athens Denton Grapevine Mansfield Sherman Wichita Falls If you have an appointment scheduled that
read more
Winter Weather Closures
Due to the winter weather, the following Texas Retina offices are CLOSED today, January 9, 2025: Dallas North Arlington Athens Frisco Denton Fort Worth Grapevine Plano Sherman Wichita Falls If you have
read more
Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read more